Document Detail


Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
MedLine Citation:
PMID:  16263826     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Vascular endothelial growth factor (VEGF) promotes placental vascularization, which is inadequate in preeclampsia and intrauterine growth retardation (IUGR). The soluble receptor of VEGF (sVEGFR-1), also known as soluble fms-like tyrosine kinase-1, is produced in the placenta and reduces VEGF activity. Therefore, elevated sVEGFR-1 could contribute to the development of preeclampsia and IUGR. OBJECTIVE: The objective of this study was to study maternal serum sVEGFR-1 concentration in early pregnancy ending in preeclampsia and IUGR. DESIGN: This was a case-control study. SETTING: This study was conducted at Helsinki University Central Hospital (Helsinki, Finland), a tertiary referral center. PATIENTS: Patients included 124 pregnant women, of whom 49 developed preeclampsia, 16 gave birth to IUGR infants without preeclampsia, and 59 remained normotensive and gave birth to normal-sized infants. Serum samples were collected at 12-15 and 16-20 gestational weeks. MAIN OUTCOME MEASURES: Serum sVEGFR-1 concentrations were determined by ELISA. RESULTS: Women with subsequent preeclampsia had higher [median; interquartile range (IQR)] concentrations of sVEGFR-1 at 16-20 wk gestation (436 and 282-699 ng/liter; P = 0.005) than the controls (296 and 184-508 ng/liter). The conclusion was the same if women with mild (340 and 285-750 ng/liter; P = 0.043) or severe (497 and 235-699 ng/liter; P = 0.022) preeclampsia were analyzed separately. An elevated sVEGFR-1 concentration at 16-20 wk gestation is associated with an increased risk of preeclampsia but not of isolated IUGR. Soluble VEGFR-1 concentration decreased by 15% from the first to the second sampling in the controls but not in women with preeclampsia or IUGR. CONCLUSION: Elevated sVEGFR-1 concentrations at 16-20 wk gestation precede the clinical manifestations of preeclampsia. By neutralizing VEGF, sVEGFR-1 may contribute to inadequate placental vascularization.
Authors:
Katja-Anneli Wathén; Eija Tuutti; Ulf-Håkan Stenman; Henrik Alfthan; Erja Halmesmäki; Patrik Finne; Olavi Ylikorkala; Piia Vuorela
Related Documents :
9727716 - Intrauterine growth retardation: evidence for the activation of the insulin-like growth...
6889066 - Sternum length, torso length, and internipple distance in newborn infants.
17057986 - Mercury and growth of tree swallows at acadia national park, and at orono, maine, usa.
3904476 - Long bone lengths and gestational age distributions of post-contact period arikara indi...
6475826 - The effect of wic supplemental feeding on birth weight: a case-control analysis.
7271286 - Breast development in the newborn.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-11-01
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  91     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-10     Completed Date:  2006-01-31     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  180-4     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki, 00029 HUS, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Fetal Development / physiology
Fetal Growth Retardation / blood*,  epidemiology
Humans
Pre-Eclampsia / blood*,  epidemiology
Pregnancy / blood*
Pregnancy Outcome
Pregnancy Trimester, First / blood
Pregnancy Trimester, Second / blood
Risk Assessment
Vascular Endothelial Growth Factor Receptor-1 / blood*
Chemical
Reg. No./Substance:
EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older...
Next Document:  Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light.